Cantor Fitzgerald Maintains Overweight on LifeMD, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has maintained an Overweight rating on LifeMD (NASDAQ:LFMD) and increased the price target from $9 to $11.
March 12, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on LifeMD and raised the price target from $9 to $11.
The upgrade in price target by a reputable analyst firm like Cantor Fitzgerald typically signals a strong confidence in the company's future performance. This can lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100